Genesis 2024 Conference

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce its attendance at the Genesis 2024 Conference, being held today, 4th December 2024, in London, UK. 

 

Genesis, delivered by One Nucleus, is a premier event for the life sciences sector bringing together global leaders in drug development, investment, and innovation. The conference offers a platform for collaboration, showcasing cutting-edge technologies and fostering partnerships that drive the future of healthcare. 

 

Physiomics’ CEO, Dr Peter Sargent, will be at the event to engage with attendees on how Physiomics expertise in pharmacokinetic/pharmacodynamic (PKPD) modelling, biostatistics, and data science supports the optimisation of drug development strategies. 

 

To schedule a meeting with the Physiomics team at Genesis 2024 please contact us at info@physiomics.com or for more information about Physiomics’ services please visit www.physiomics.co.uk 

  

 

Enquiries: 

Physiomics plc 

Dr Peter Sargent, Chief Executive Officer

+44 (0)1865 784 980 

  

Hybridan LLP (Broker) 

Claire Louise Noyce 

+44 (0) 203 764 2341 

  

Strand Hanson Ltd (NOMAD) 

James Dance & James Bellman 

+44 (0)20 7409 3494 

   

  

Notes to Editor 

   

About Physiomics 

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies. 

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.